Right and left hemisphere brain surface plots showing the strength of the canonical vec-tor, νƙ, for each subtype are represented in this figure from a study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics,” presented June 27 during the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI 2023 held in Chicago, IL. Image provided by SNMMI created by Fan Yang, University of Massachusetts, Amherst.
June 29, 2023 — Research presented at the 2023 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, SNMMI 2023, held in Chicago this week, showed a new computational technique — one which combines genomic and tau PET imaging data — promises a more personalized approach for subtyping Alzheimer’s disease. Based on a novel clustering framework using sparse canonical correlation analysis (SCCA), the integrated approach was successful in identifying four subtypes of Alzheimer’s disease and the top genes associated with each, according to the authors of the study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics.”
Alzheimer’s disease is a genetically complex disorder. Several subtypes of the disease have been identified based on PET imaging of amyloid plaques and tau neurofibrillary tangles, the pathological hallmarks of the disease. In addition, recent genome-wide association studies have identified many genes that play a role in the development of Alzheimer’s disease.
“By identifying different subtypes of Alzheimer’s disease using both imaging and genomic information, researchers could gain potential new insights into the underlying biology of the disease and its progression,” stated Joyita Dutta, PhD, associate professor in the Department of Biomedical Engineering at the University of Massachusetts in Amherst, Massachusetts. She further noted, “Understanding the specific genetic associations for each subtype could also lead to the development of personalized treatment approaches in the future.”
Imaging and genomics data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were utilized in the investigation. All ADNI participants who had undergone 18F-flortaucipir PET and Illumina SNP genotyping were included (541 participants in total; 334 cognitively normal and 207 cognitively impaired). Tau PET standardized uptake value ratios from 10 broad regions were computed from tau PET imaging, and 145 genome variations associated with Alzheimer's disease were identified and extracted from the SNP genotyping. The SCCA-clustering framework was then jointly applied to the tau PET and genomics datasets.
Four subtypes of Alzheimer’s disease were identified in the analysis: medial temporal lobe (MTL)-dominant, posterior, MTL-sparing, and lateral-temporal. In addition to the APOE gene, top genes that were associated with each subtype were also identified.
“Genomics- and imaging-guided individualized subtyping is vital for Alzheimer’s disease because different subtypes may also have distinct rates and profiles of cognitive decline, potentially affecting clinical trial outcomes and treatment response,” said Dutta. “By combining molecular imaging information with genomics, we have created a diagnostic technique that could be truly personalized for each patient. This has potential for broad diagnostic utility across many disease types, not only Alzheimer’s disease,” Dutta added.
Authors of the study were Fan Yang and Joyita Dutta, University of Massachusetts, Amherst, Massachusetts; Matthew Maher and Richa Saxena, Massachusetts General Hospital, Boston, Massachusetts.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. As noted by the organization, its members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice.
More information: www.snmmi.org
Find more ITN coverage of SNMMI 2023 news here.
July 30, 2024 
